Ivermectin shows promise in reducing viral load of Covid-19 in clinical trial: icddr,b study

Investigators at the icddr,b said specific doses of the anti-parasitic drug Ivermectin significantly reduce the viral load of Covid-19 if administered during the first five days of infection.

Experts lauded the first ever randomised clinical trial on the drug, saying this can be helpful for physicians.

However, a large-scale clinical trial will have to be carried out to reach a conclusion about the effectiveness of this drug in Covid-19 treatment, they said.

They suggested not to take the drug without physicians' advice.

Icddr,b revealed the study supported by Beximco Pharmaceuticals Ltd at an event in Dhaka today.